Deals this week: Optinose, Cofactor Genomics, MediWound

21 September 2017 (Last Updated September 21st, 2017 18:30)

Optinose Inc is planning an initial public offering of shares of its common stock to raise $100m.

Optinose Inc is planning an initial public offering of shares of its common stock to raise $100m.

Based in the US, Optinose is a nasal delivery technology developer. The company plans to use the proceeds from the offering to advance the development of its XHANCE product and for general corporate purposes.

Cofactor Genomics Inc has secured $18m in a series A funding round led by Menlo Ventures and joined by existing investor Data Collective Venture Capital LLC.

The US-based biotech company involved in developing RNA-based diagnostic kits plans to use the funds to enhance its research and development.

"The UK-based robotic systems developer secured $20.3m in July in a series A funding round led by ABB Technology Ventures, bringing the total funds to $46m."

MediWound Ltd plans for an underwritten public offering of shares. The offering also includes a 30-day option for underwriters to purchase 15% of ordinary shares.

The Israeli biotech company plans to use the funds towards research and development, as well as general corporate purposes.

Cambridge Medical Robotics Ltd (CMR) has secured an additional $26m in a series A funding round headed by Watrium and ABB Technology Ventures.

The UK-based robotic systems developer secured $20.3m in July in a series A funding round led by ABB Technology Ventures, bringing the total funds to $46m. The company plans to use the stocks to advance the development of its Versius surgical robotic system.